Toll Free: 1-888-928-9744

Polyphor Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Polyphor Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Polyphor Ltd. - Product Pipeline Review - 2014', provides an overview of the Polyphor Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Polyphor Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Polyphor Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Polyphor Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Polyphor Ltd.'s pipeline products

Reasons to buy

- Evaluate Polyphor Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Polyphor Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Polyphor Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Polyphor Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Polyphor Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Polyphor Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Polyphor Ltd. Snapshot 5
Polyphor Ltd. Overview 5
Key Information 5
Key Facts 5
Polyphor Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Polyphor Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Polyphor Ltd. - Pipeline Products Glance 15
Polyphor Ltd. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Polyphor Ltd. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Polyphor Ltd. - Drug Profiles 19
POL-6326 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
POL-5551 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
POL-6014 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
POL-6926 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
POL-7080 Follow-On 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
POL-7085 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule for Undisclosed Indication 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PEM Candidates 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules for Infectious Diseases 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Synthetic Peptides to Inhibit Proteases for Respiratory and Cardiovascular Diseases 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Polyphor Ltd. - Pipeline Analysis 34
Polyphor Ltd. - Pipeline Products by Target 34
Polyphor Ltd. - Pipeline Products by Route of Administration 35
Polyphor Ltd. - Pipeline Products by Molecule Type 36
Polyphor Ltd. - Pipeline Products by Mechanism of Action 37
Polyphor Ltd. - Recent Pipeline Updates 38
Polyphor Ltd. - Dormant Projects 39
Polyphor Ltd. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42
List of Tables
Polyphor Ltd., Key Information 5
Polyphor Ltd., Key Facts 5
Polyphor Ltd. - Pipeline by Indication, 2014 8
Polyphor Ltd. - Pipeline by Stage of Development, 2014 9
Polyphor Ltd. - Monotherapy Products in Pipeline, 2014 10
Polyphor Ltd. - Partnered Products in Pipeline, 2014 11
Polyphor Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
Polyphor Ltd. - Out-Licensed Products in Pipeline, 2014 13
Polyphor Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14
Polyphor Ltd. - Phase II, 2014 15
Polyphor Ltd. - Phase I, 2014 16
Polyphor Ltd. - Preclinical, 2014 17
Polyphor Ltd. - Discovery, 2014 18
Polyphor Ltd. - Pipeline by Target, 2014 34
Polyphor Ltd. - Pipeline by Route of Administration, 2014 35
Polyphor Ltd. - Pipeline by Molecule Type, 2014 36
Polyphor Ltd. - Pipeline Products by Mechanism of Action, 2014 37
Polyphor Ltd. - Recent Pipeline Updates, 2014 38
Polyphor Ltd. - Dormant Developmental Projects,2014 39 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify